Transcatheter aortic valve replacement is a safe and effective alternative to surgery in patients with severe aortic stenosis and high surgical risk as the 5-year results of PARTNER 1 Alternate showed. The aim of this study was to evaluate the result of the Edwards Sapien 3 valve in patients with severe aortic stenosis and intermediate risk with surgery indication. 101 patients with a mean age of 84.4 years, who had mortality rate of just 1.1% despite a predicted mortality of 30 days, were included. The rate of stroke (4%) was also low with a significant improvement from the previous generation of devices. The need for permanent pacemaker was 4.2% and severe aortic insufficiency 2.3%.
Conclusion
Intermediate-risk patients treated with the Edwards Sapiens 3 valve, the mortality and complications were generally very low.
Alec Vahanian
2015-05-20
Original title: 30-day outcomes of intermediate-risk patients with the new generation balloon-expandable transcatheter heart valve via the transfemoral approach – SAPIENS 3 Trial.
